Zhang Yongmei, Ju Zhinan, Dai Kanghui, Wan Liqun, Zhou Guangmao, Ji Yanchun, Qiu Jiehua
Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University, Nanchang , Jiangxi, 330006, China.
Department of Vascular Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang , Jiangxi, 330006, China.
BMC Cardiovasc Disord. 2025 May 31;25(1):423. doi: 10.1186/s12872-025-04821-6.
This study aimed to investigate the potential involvement of 5'-AMP-activated protein kinase (AMPK) in the pathogenesis of lower-extremity varicose veins (VV).
In this study, 8 patients with CEAP stage C6 chronic venous disease and 8 age-matched healthy controls were prospectively recruited to collect samples for preparation of subsequent experiments.None of the patients included in the molecular analyses were diagnosed with diabetes, as our analysis of 73,313 patients demonstrated that diabetes is generally not associated with VV. Western blotting was employed to quantify the levels of p-AMPK, G-actin, p-tubulin, p-HSP20, and 14-3-3 proteins in each sample.
Epidemiological analyses revealed 5,262 patients with VVs among 714,789 inpatients. Of these patients, only 351 VV patients were diagnosed with type 2 DM, while 4,911 were not diagnosed with DM. Higher levels of AMPK activation were evident in VV samples in molecular analyses, with the p-AMPK level in the VV group being 1.98 ± 0.56 times higher than that in the NV group (n = 3, P < 0.001). G-actin levels in VV samples were additionally 2.14 ± 0.60 times higher than those in NV samples (n = 3, P < 0.001). Increased cofilin activation was also observed in VV samples, as evidenced by p-cofilin levels in the VV group that were 0.63 ± 0.10 times those in the NV group (n = 3, P < 0.001), with VV samples additionally exhibiting p-HSP20 levels that were 2.02 ± 0.59 times higher than those in NV samples (n = 3, P < 0.001).
These results suggest that AMPK Is likely to be involved lower extremity VV development, potentially by inducing vasodilation through the dysregulation of F-actin cytoskeletal dynamics in VSMCs, increasing cofilin activation, the displacement of which from 14-3-3 can lead to dephosphorylation mediated by HSP20,and then causes its dephosphorylation and increased activity, and thereby reducing cytoskeletal actin homeostasis and promoting vascular relaxation.These findings elucidate the possible regulatory role of AMPK phosphorylation in vein wall degeneration and provide a theoretical basis for further studies.
本研究旨在探讨5′-AMP激活蛋白激酶(AMPK)在下肢静脉曲张(VV)发病机制中的潜在作用。
本研究前瞻性招募了8例CEAP C6期慢性静脉疾病患者和8例年龄匹配的健康对照者,采集样本用于后续实验准备。纳入分子分析的患者均未诊断为糖尿病,因为我们对73313例患者的分析表明,糖尿病通常与VV无关。采用蛋白质免疫印迹法对每个样本中p-AMPK、G-肌动蛋白、p-微管蛋白、p-HSP20和14-3-3蛋白的水平进行定量分析。
流行病学分析显示,在714789例住院患者中有5262例患有VV。其中,只有351例VV患者被诊断为2型糖尿病,而4911例未被诊断为糖尿病。分子分析显示VV样本中AMPK激活水平较高,VV组p-AMPK水平比非VV组高1.98±0.56倍(n = 3,P < 0.001)。VV样本中G-肌动蛋白水平比非VV样本高2.14±0.60倍(n = 3,P < 0.001)。在VV样本中还观察到丝切蛋白激活增加,VV组p-丝切蛋白水平是非VV组的0.63±0.10倍(n = 3,P < 0.001),并且VV样本中p-HSP20水平比非VV样本高2.02±0.59倍(n = 3,P < 0.001)。
这些结果表明,AMPK可能参与下肢VV发展,可能是通过平滑肌细胞中F-肌动蛋白细胞骨架动力学失调诱导血管舒张,增加丝切蛋白激活,其从14-3-3的移位可导致HSP20介导的去磷酸化,进而导致其去磷酸化并增加活性,从而破坏细胞骨架肌动蛋白稳态并促进血管舒张。这些发现阐明了AMPK磷酸化在静脉壁退变中的可能调节作用,并为进一步研究提供了理论基础。